ExThera Medical

ExThera Medical is a medical technology company focused on developing and commercializing extracorporeal blood filtration devices. Their key products include the Seraph® 100 Microbind® Affinity Blood Filter and the ONCObind™ Blood Filter. These devices are designed to remove harmful substances from the bloodstream, showing significant potential in treating critically ill patients, particularly those with severe infections and stage 4 metastatic cancer. The Seraph 100 filter utilizes a unique microbead adsorption technology that effectively removes viruses, including COVID-19, from circulation. This innovative approach addresses critical clinical needs in areas such as sepsis and COVID-19 treatment. Founded in 2007, ExThera Medical is dedicated to combating antimicrobial resistance and advancing therapeutic blood filtration technologies, supported by independent clinical studies and ongoing trials. The company serves healthcare professionals and patients in the U.S. and European Union, with a leadership team that includes experienced professionals from various medical and business backgrounds. ExThera Medical is committed to improving patient outcomes through its advanced blood filtration solutions.

• Employees 43
• Founded 2007
• Annual Revenue $7200000
• Total Funding $56104506